表紙
市場調查報告書

生長抑制素類似體的全球市場:各類型,應用及各地區的市場規模,佔有率及趨勢分析報告,各市場區隔預測(2019年∼2026年)

Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, Neuroendocrine Tumors), By Region And Segment Forecasts, 2019 - 2026

出版商 Grand View Research, Inc. 商品編碼 916986
出版日期 內容資訊 英文 90 Pages
商品交期: 2-3個工作天內
價格
Back to Top
生長抑制素類似體的全球市場:各類型,應用及各地區的市場規模,佔有率及趨勢分析報告,各市場區隔預測(2019年∼2026年) Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, Neuroendocrine Tumors), By Region And Segment Forecasts, 2019 - 2026
出版日期: 2019年10月11日內容資訊: 英文 90 Pages
簡介

全球生長抑制素類似體治療藥的市場規模預計將以6.3%的年複合成長率擴大,至2026年達到89億美元。肢端肥大症和神經內分泌腫瘤等疾病的認識的高漲,預計對成長要素帶來重要的影響。 還有強力開發中產品的存在,成為在預測期間內的市場推動成長的主要要素之一。

本報告提供全球生長抑制素類似體市場相關調查分析,市場預測,各市場區隔預測,加上競爭情形相關的系統性資訊。

目錄

第1章 調查方法與範圍

  • 市場區隔和範圍
  • 市場定義
  • 資訊採購
  • 資訊分析
  • 市場定式化及資料的視覺化
  • 資料的檢驗及公開

第2章 摘要整理

  • 市場預測
  • 市場區隔預測
  • 競爭的考察

第3章 市場變數,趨勢及規模

  • 市場系統預測
  • 市場滲透及成長預測的製圖
  • 開發平台分析
  • 市場動態
  • PESTEL分析
  • 主要交易及策略性聯盟分析

第4章 競爭分析

  • 各主要市場參與者最新趨勢及影響分析
  • 企業/競爭的分類(主要創新者,市場領導,新興企業)
  • 公開公司
  • 私人公司

第5章 各類型評估及趨勢分析

  • 定義及範圍
  • 類型市場佔有率分析,2018年及2026年
  • 類型儀表板
  • 各類型市場,2015年∼2026年
  • 市場規模、預測及趨勢分析,2015年∼2026年
    • Lanreotide
    • Octreotide
    • Pasireotide

第6章 各應用領域評估及趨勢分析

  • 定義及範圍
  • 應用市場佔有率分析,2018年及2026年
  • 應用儀表板
  • 各應用領域,2015年∼2026年
  • 市場規模、預測及趨勢分析,2015年∼2026年
    • 肢端肥大症
    • 神經內分泌腫瘤(NET)
    • 其他

第7章 各地區評估及趨勢分析,各類型、應用領域

  • 各地區市場的概述
  • 各地區市場佔有率及主要企業,2018年
  • 各要因SWOT分析(政治,法律,經濟,技術性)
  • 市場規模、預測及趨勢分析,2015年∼2026年

第8章 公司概要

  • 策略性架構
目錄
Product Code: GVR-3-68038-789-6

The global somatostatin analogs treatment market size is expected to reach USD 8.9 billion by 2026, expanding at a CAGR of 6.3% during the forecast period, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Presence of strong pipeline products is one of the major factors driving the market growth over the forecast period. For instance, Camurus AB is developing CAM2029 for the treatment of acromegaly and is currently under phase 3 clinical trial. This product comprises of octreotide as its main ingredient. The product is also under phase 1/2 trials for the treatment of neuroendocrine tumors. Furthermore, Dauntless Pharmaceuticals is developing DP1038, an intranasal octreotide, and is currently under clinical development.

Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

In addition, this network exhibits at the medical trade shows and medical meetings such as NANETs, ASCO, Healing NET Foundation, ASCO GI, The American Association of Endocrine Surgeons, Interventional Radiology, Digestive Disease Week, and local fairs to create awareness pertaining to NETs among population.

In addition, in January 2018, Midatech Pharma PLC received confirmation in oral formulation from Polish regulators for its first in-human analysis of sustained release product Q-Octreotide (MTD201). The product is aimed to be used as an alternative of the commercial leading product, Sandostatin LAR.

Presence of key players such as Novartis AG, Ipsen Pharma, Pfizer Inc., Sun Pharmaceutical Industries Ltd and Chiasma Inc. is expected to fuel to the overall market growth. Involvement of major players in new product development is considered to be the high contributing factor for the SSAs market.

Further key findings from the report suggest:

  • Octreotide held the largest market share in 2018 due to its various therapeutic applications
  • Pasireotide is estimated to be the fastest growing segment over the forecast period
  • Acromegaly held the largest share in 2018 owing to its increase prevalence
  • North America dominated the market in 2018 owing to presence of key players such as Pfizer Inc. and Novartis AG
  • Asia Pacific is estimated to be the fastest growing segment with a CAGR of 9.0% over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Market definition
  • 1.3. Information procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & third party perspectives
    • 1.3.4. Primary research
  • 1.4. Information analysis
    • 1.4.1. Data analysis models
  • 1.5. Market formulation & data visualization
  • 1.6. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Somatostatin Analogs Market Variables, Trends & Scope

  • 3.1. Somatostatin Analogs Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Pipeline Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Increasing incidence and prevalence of acromegaly, NETs
      • 3.4.1.2. Presence of pipeline products
      • 3.4.1.3. Increasing investments in R&D activities
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. High cost of treatment
    • 3.4.3. Industry Analysis - Porter's
      • 3.4.3.1. Supplier Power
      • 3.4.3.2. Buyer Power
      • 3.4.3.3. Substitution Threat
      • 3.4.3.4. Threat from new entrant
      • 3.4.3.5. Competitive rivalry
  • 3.5. PESTEL Analysis
    • 3.5.1. Political Landscape
    • 3.5.2. Environmental Landscape
    • 3.5.3. Social Landscape
    • 3.5.4. Technology Landscape
    • 3.5.5. Legal Landscape
  • 3.6. Major Deals & Strategic Alliances Analysis
    • 3.6.1. Joint Ventures
    • 3.6.2. Mergers & Acquisitions
    • 3.6.3. Licensing & Partnership
    • 3.6.4. Technology Collaborations
    • 3.6.5. Strategic Divestments

Chapter 4. Somatostatin Analogs Market - Competitive Analysis

  • 4.1. Recent developments & impact analysis, by key market participants
  • 4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 4.3. Public Companies
    • 4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 4.3.2. Competitive Dashboard Analysis
    • 4.3.3. Market Differentiators
    • 4.3.4. Synergy Analysis: Major Deals & Strategic Alliances
  • 4.4. Private Companies
    • 4.4.1. List of key emerging companies
    • 4.4.2. Regional network map

Chapter 5. Somatostatin Analogs Market: Type Estimates & Trend Analysis

  • 5.1. Definitions & Scope
  • 5.2. Type market share analysis, 2018 & 2026
  • 5.3. Type Dashboard
  • 5.4. Global Somatostatin Analogs Market, by Type, 2015 to 2026
  • 5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
    • 5.5.1. Lanreotide
      • 5.5.1.1. Lanreotide market, 2015 - 2026 (USD Million)
    • 5.5.2. Octreotide
      • 5.5.2.1. Octreotide market, 2015 - 2026 (USD Million)
    • 5.5.3. Pasireotide
      • 5.5.3.1. Pasireotide market, 2015 - 2026 (USD Million)

Chapter 6. Somatostatin Analogs Market: Application Estimates & Trend Analysis

  • 6.1. Definitions & Scope
  • 6.2. Application market share analysis, 2018 & 2026
  • 6.3. Application Dashboard
  • 6.4. Global Somatostatin Analogs Market, by Application, 2015 to 2026
  • 6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
    • 6.5.1. Acromegaly
      • 6.5.1.1. Acromegaly market, 2015 - 2026 (USD Million)
    • 6.5.2. Neuroendocrine Tumors (NETs)
      • 6.5.2.1. NETs market, 2015 - 2026 (USD Million)
    • 6.5.3. Others
      • 6.5.3.1. Others market, 2015 - 2026 (USD Million)

Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis, by Type, Application

  • 7.1. Regional Market Snapshot
  • 7.2. Regional Market Share and Leading Players, 2018
  • 7.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.3.1. North America
    • 7.3.2. Europe
    • 7.3.3. Asia Pacific
    • 7.3.4. Latin America
    • 7.3.5. Middle East & Africa
  • 7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
    • 7.4.1. North America
      • 7.4.1.1. North America Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.1.2. U.S.
      • 7.4.1.2.1. U.S. Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.1.3. Canada
      • 7.4.1.3.1. Canada Somatostatin Analogs Market, 2015 - 2026 (USD Million)
    • 7.4.2. Europe
      • 7.4.2.1. Europe Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.2.2. UK
      • 7.4.2.2.1. UK Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.2.3. Germany
      • 7.4.2.3.1. Germany Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.2.4. Spain
      • 7.4.2.4.1. Spain Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.2.5. France
      • 7.4.2.5.1. France Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.2.6. Italy
      • 7.4.2.6.1. Italy Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.2.7. Russia
      • 7.4.2.7.1. Russia Somatostatin Analogs Market, 2015 - 2026 (USD Million)
    • 7.4.3. Asia Pacific
      • 7.4.3.1. Asia Pacific Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.3.2. China
      • 7.4.3.2.1. China Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.3.3. Japan
      • 7.4.3.3.1. Japan Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.3.4. India
      • 7.4.3.4.1. India Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.3.5. South Korea
      • 7.4.3.5.1. South Korea Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.3.6. Australia
      • 7.4.3.6.1. Australia Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.3.7. Singapore
      • 7.4.3.7.1. Singapore Somatostatin Analogs Market, 2015 - 2026 (USD Million)
    • 7.4.4. Latin America
      • 7.4.4.1. Latin America Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.4.2. Brazil
      • 7.4.4.2.1. Brazil Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.4.3. Mexico
      • 7.4.4.3.1. Mexico Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.4.4. Argentina
      • 7.4.4.4.1. Argentina Somatostatin Analogs Market, 2015 - 2026 (USD Million)
    • 7.4.5. Middle East Africa
      • 7.4.5.1. MEA Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.5.2. South Africa
      • 7.4.5.2.1. South Africa Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.5.3. Saudi Arabia
      • 7.4.5.3.1. Saudi Arabia Somatostatin Analogs Market, 2015 - 2026 (USD Million)
      • 7.4.5.4. UAE
      • 7.4.5.4.1. UAE Somatostatin Analogs Market, 2015 - 2026 (USD Million)

Chapter 8. Company Profiles

  • 8.1. Strategic Framework
    • 8.1.1. Novartis AG
      • 8.1.1.1. Company overview
      • 8.1.1.2. Financial framework
      • 8.1.1.3. Product benchmarking
      • 8.1.1.4. Strategic initiatives
    • 8.1.2. Sun Pharmaceutical Industries Ltd
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial framework
      • 8.1.2.3. Product benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. Midatech Pharma PLC
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial framework
      • 8.1.3.3. Product benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. Ipsen Pharma
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial framework
      • 8.1.4.3. Product benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. Chiasma, Inc.
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial framework
      • 8.1.5.3. Product benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. Peptron, Inc.
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial framework
      • 8.1.6.3. Product benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. CRINETICS PHARMACEUTICALS
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial framework
      • 8.1.7.3. Product benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. Dauntless Pharmaceuticals
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial framework
      • 8.1.8.3. Product benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. Camurus AB
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial framework
      • 8.1.9.3. Product benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Teva Pharmaceuticals Inc.
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial framework
      • 8.1.10.3. Product benchmarking
      • 8.1.10.4. Strategic initiatives
    • 8.1.11. Pfizer Inc.
      • 8.1.11.1. Company overview
      • 8.1.11.2. Financial framework
      • 8.1.11.3. Product benchmarking
      • 8.1.11.4. Strategic initiatives

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 3 North America Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 4 U.S. Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 5 U.S. Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 6 Canada Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 7 Canada Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 8 Europe Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 9 Europe Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 10 UK Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 11 UK Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 12 Germany Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 13 Germany Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 14 France Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 15 France Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 16 Italy Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 17 Italy Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 18 Spain Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 19 Spain Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 20 Asia Pacific Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 21 Asia Pacific Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 22 Japan Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 23 Japan Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 24 China Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 25 China Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 26 India Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 27 India Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 28 South Korea Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 29 South Korea Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 30 Australia Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 31 Australia Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 32 Singapore Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 33 Singapore Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 34 Latin America Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 35 Latin America Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 36 Mexico Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 37 Mexico Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 38 Brazil Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 39 Brazil Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 40 Argentina Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 41 Argentina Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 42 MEA Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 43 MEA Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 44 South Africa Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 45 South Africa Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 46 Saudi Arabia Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 47 Saudi Arabia Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
  • TABLE 48 UAE Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
  • TABLE 49 UAE Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global somatostatin analogs market- Key market driver analysis
  • FIG. 7 Global somatostatin analogs market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global somatostatin analogs market - Porter's analysis
  • FIG. 10 Global somatostatin analogs market - PESTEL analysis
  • FIG. 11 Global somatostatin analogs market type outlook key takeaways
  • FIG. 12 Global somatostatin analogs market: Type movement analysis
  • FIG. 13 Octreotide market estimates, 2015 - 2026 (USD Million)
  • FIG. 14 Lanreotide market estimates, 2015 - 2026 (USD Million)
  • FIG. 15 Pasireotide market estimates, 2015 - 2026 (USD Million)
  • FIG. 16 Global somatostatin analogs market Application outlook key takeaways
  • FIG. 17 Global somatostatin analogs market: Application movement analysis
  • FIG. 18 Acromegaly market estimates, 2015 - 2026 (USD Million)
  • FIG. 19 NETs market estimates, 2015 - 2026 (USD Million)
  • FIG. 20 Others market estimates, 2015 - 2026 (USD Million)
  • FIG. 21 Global somatostatin analogs market: Regional movement analysis
  • FIG. 22 North America somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 23 U.S. somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 24 Canada somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 25 Europe somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 26 U.K. somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 27 Germany somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 28 France somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 29 Spain somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 30 Italy somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 31 Asia Pacific somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 32 Japan somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 33 China somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 34 India somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 35 South Korea somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 36 Australia somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 37 Singapore somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 38 Latin America somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 39 Brazil somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 40 Mexico somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 41 Argentina somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 42 MEA somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 43 South Africa somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 44 Saudi Arabia somatostatin analogs market, 2015 - 2026 (USD Million)
  • FIG. 45 UAE market, 2015 - 2026 (USD Million)
  • FIG. 46 Strategy framework
Back to Top